

Comprehensive functional annotation of susceptibility variants identifies genetic heterogeneity between lung adenocarcinoma and squamous cell carcinoma

Na Qin^{1,*}, Yuancheng Li^{1,*}, Cheng Wang^{1,2,3}, Meng Zhu^{1,4}, Juncheng Dai^{1,2,4,5}, Tongtong Hong¹, Demetrius Albanes⁶, Stephen Lam⁷, Adonina Tardon⁸, Chu Chen⁹, Gary Goodman¹⁰, Stig E. Bojesen¹¹, Maria Teresa Landi¹², Mattias Johansson¹³, Angela Risch¹⁴, H-Erich Wichmann¹⁵, Heike Bickeboller¹⁶, Gadi Rennert¹⁷, Susanne Arnold¹⁸, Paul Brennan¹³, John K. Field¹⁹, Sanjay Shete²⁰, Loic Le Marchand²¹, Olle Melander²², Hans Brunnstrom²², Geoffrey Liu²³, Rayjean J. Hung²⁴, Angeline Andrew²⁵, Lambertus A. Kiemeny²⁶, Shan Zienoldiny²⁷, Kjell Grankvist²⁸, Mikael Johansson²⁹, Neil Caporaso³⁰, Penella Woll³¹, Philip Lazarus³², Matthew B. Schabath³³, Melinda C. Aldrich³⁴, Victoria L. Stevens³⁵, Guangfu Jin^{1,2,4,5}, David C. Christiani^{5,36}, Zhibin Hu^{1,2,5}, Christopher I. Amos³⁷, Hongxia Ma (✉)^{1,2,4,5}, Hongbing Shen (✉)^{1,2,4,5}

¹Department of Epidemiology, Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing 211166, China; ²State Key Laboratory of Reproductive Medicine, Center for Global Health, Nanjing Medical University, Nanjing 211166, China; ³Department of Bioinformatics, School of Biomedical Engineering and Informatics, Nanjing Medical University, Nanjing 211166, China; ⁴Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Medicine, Nanjing Medical University, Nanjing 211166, China; ⁵China International Cooperation Center for Environment and Human Health, School of Public Health, Nanjing Medical University, Nanjing 211166, China; ⁶Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD 20892-9304, USA; ⁷Department of Integrative Oncology, British Columbia Cancer Agency, Vancouver, BC V5Z 1L3, Canada; ⁸Faculty of Medicine, University of Oviedo and CIBERESP, Oviedo 33006, Spain; ⁹Program in Epidemiology, Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109-1024, USA; ¹⁰Public Health Sciences Division, Swedish Cancer Institute, Seattle, WA 98026, USA; ¹¹Department of Clinical Biochemistry, Copenhagen University Hospital, Copenhagen DK-1017, Denmark; ¹²National Cancer Institute, Bethesda, MD 20892-9304, USA; ¹³Genetic Epidemiology Group, International Agency for Research on Cancer, Lyon 69372, France; ¹⁴Cancer Center Cluster Salzburg at PLUS, Department of Molecular Biology, University of Salzburg, Heidelberg 5020, Austria; ¹⁵Institute of Medical Informatics, Biometry and Epidemiology, Chair of Epidemiology, Ludwig Maximilians University, Munich, Bavaria 80539, Germany; ¹⁶Department of Genetic Epidemiology, University Medical Center Goettingen, Goettingen 37075, Germany; ¹⁷Technion Faculty of Medicine, Carmel Medical Center, Haifa 3448516, Israel; ¹⁸Markey Cancer Center, University of Kentucky, Lexington, KY 40506-0054, USA; ¹⁹Department of Molecular and Clinical Cancer Medicine, Roy Castle Lung Cancer Research Programme, The University of Liverpool Institute of Translational Medicine, Liverpool L69 7ZX, UK; ²⁰Department of Epidemiology, The University of Texas, MD Anderson Cancer Center, Houston, TX 77079, USA; ²¹Department of Epidemiology, University of Hawaii Cancer Center, Honolulu, HI 96813, USA; ²²Department of Clinical Sciences, Lund University, BMC F12, 221 84, Sweden; ²³Epidemiology Division, Princess Margaret Cancer Center, Toronto, ON M4Y 2H8, Canada; ²⁴Epidemiology Division, Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, ON M5G 1X5, Canada; ²⁵Department of Neurology, Dartmouth-Hitchcock Medical Center, Lebanon, NH 03756, USA; ²⁶Department of Health Evidence, Radboud University Medical Center, Nijmegen 9101 6500 HB, Germany; ²⁷National Institute of Occupational Health (STAMI), Oslo Pb 5330, Norway; ²⁸Department of Medical Biosciences, Umeå University, Umeå 901 87, Sweden; ²⁹Department of Radiation Sciences, Umeå University, Umeå 901 87, Sweden; ³⁰Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD 20850, USA; ³¹Academic Unit of Clinical Oncology, University of Sheffield, Sheffield S10 2TN, UK; ³²College of Pharmacy, Washington State University, Spokane, WA 99210, USA; ³³Department of Cancer Epidemiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 12902, USA; ³⁴Department of Thoracic Surgery, Division of Epidemiology, Vanderbilt University Medical Center, Nashville, TN 37232, USA; ³⁵Department of Epidemiology Research Program, American Cancer Society, Atlanta, GA 30303, USA; ³⁶Department of Environmental Health, Harvard School of Public Health, Department of Medicine, Harvard Medical School/Massachusetts General Hospital, Boston, MA 02115, USA; ³⁷Baylor College of Medicine, Institute for Clinical and Translational Research, Houston, TX 21202, USA

© Higher Education Press 2020

Received October 13, 2019; accepted March 5, 2020

Correspondence: Hongbing Shen, hbshen@njmu.edu.cn;

Hongxia Ma, hongxiama@njmu.edu.cn

*These authors contributed equally to this work.

Abstract Although genome-wide association studies have identified more than eighty genetic variants associated with non-small cell lung cancer (NSCLC) risk, biological mechanisms of these variants remain largely unknown. By integrating a large-scale genotype data of 15 581 lung adenocarcinoma (AD) cases, 8350 squamous cell carcinoma (SqCC) cases, and 27 355 controls, as well as multiple transcriptome and epigenomic databases, we conducted histology-specific meta-analyses and functional annotations of both reported and novel susceptibility variants. We identified 3064 credible risk variants for NSCLC, which were overrepresented in enhancer-like and promoter-like histone modification peaks as well as DNase I hypersensitive sites. Transcription factor enrichment analysis revealed that USF1 was AD-specific while CREB1 was SqCC-specific. Functional annotation and gene-based analysis implicated 894 target genes, including 274 specifics for AD and 123 for SqCC, which were overrepresented in somatic driver genes (ER=1.95, $P=0.005$). Pathway enrichment analysis and Gene-Set Enrichment Analysis revealed that AD genes were primarily involved in immune-related pathways, while SqCC genes were homologous recombination deficiency related. Our results illustrate the molecular basis of both well-studied and new susceptibility loci of NSCLC, providing not only novel insights into the genetic heterogeneity between AD and SqCC but also a set of plausible gene targets for post-GWAS functional experiments.

Keywords lung cancer; genome-wide association study; function annotation; immune; homologous recombination repair deficiency; genetic heterogeneity

Introduction

Lung cancer is the leading cause of cancer morbidity and mortality worldwide [1]. Non-small cell lung cancer (NSCLC) is the main type of lung cancer, accounting for ~85% of all lung cancer cases [2]. Adenocarcinoma (AD) and squamous cell carcinoma (SqCC) represent the two major histological subtypes of NSCLC. Although tobacco smoking is generally considered as the major cause of lung cancer, genetic factors also play an important role in the development of lung cancer. Genome-wide association studies (GWASs) have previously identified 81 lung cancer susceptibility variants in 51 loci that robustly associated with lung cancer risk [3,4]; however, only a relatively small proportion of lung cancer heritability (0.7%–2.4%) can be explained by the variants identified so far [5,6]. Additionally, delineating the biological mechanism of susceptibility variants underlying the development of lung cancer has also lagged far behind [3].

The challenge of pinpointing predisposition genes in susceptibility loci lies in several aspects. First, most GWAS implicated variants are *tag* single-nucleotide polymorphisms (SNPs) which represent for all co-inherited SNPs in the same haplotype, and thus the direct inference of statistically associated SNPs rarely yields functional variants [7]. Second, as the vast majority (> 80%) of the GWAS hits are located in the non-coding regions, distinguishing functional SNPs from non-functional ones can be a great challenge [8]. Third, as previous studies mainly focused on mixed NSCLC, the biological and genomic heterogeneity of lung AD and SqCC [9–11] also

leads to a disparity of functional signals. Thus, further dissection of the genetic underpinnings of lung AD and SqCC is crucial for the understanding of lung cancer pathogenesis.

In recent years, the emergence of epigenomic data sets, such as the Encyclopedia of DNA Elements (ENCODE) project [12], the Functional Annotation of the Mammalian Genome (FANTOM) project [13], and the Roadmap Epigenomics project [14] provided a good opportunity to unveil the function of disease-associated signals from epigenomic level. By leveraging the wealth epigenomic data, many studies have attempted to illuminate the biological meanings of GWAS-implicated cancer risk loci. For example, a study from Michailidou *et al.* [15] examined the overlap of breast cancer variants with *cis*-regulatory elements (CREs) and observed a significant enrichment. Similar results were observed for the risk loci of colorectal, head and neck, ovary, and prostate cancers [16], and such CREs were active in disease-related cell lines [17]. Thus, incorporating functional information into association signals has the potential to improve our understanding of the biological consequences of human cancers.

In this study, we first conducted histology-specific genome-wide meta-analyses and then performed a comprehensive functional annotation of NSCLC susceptibility variants by integrating multiple in-house and publicly available databases. Our results first illustrate the molecular basis of all known susceptibility loci of lung cancer and provide novel insights into the genetic heterogeneity between lung AD and SqCC.

Materials and methods

Study populations

We conducted a meta-analysis with 27 120 NSCLC cases (15 581 AD, 8350 SqCC, and 3189 other cases) and 27 355 controls. Of all subjects, 26 655 Chinese participants were from our previously published Nanjing Medical University (NJMU) lung cancer GWAS study [4] and 27 820 European participants were from the TRICL-ILCCO OncoArray project [18]. NJMU lung cancer GWAS study consisted of three data sets, including 19 546 participants (10 248 cases and 9298 controls) from NJMU Global Screening Array (GSA) project [4], 5203 participants (2126 cases and 3077 controls) from NJMU GWAS project [19], and 1906 participants (953 cases and 953 controls) from NJMU OncoArray project [4]. Informed consent was obtained from all the participants included in this study, and each study was approved by the corresponding institutional review board. Detailed demographic characteristics of included participants have been described in our previous study [4], and were provided in Table 1.

Quality control and imputation

Detailed imputation process has been described in our previous study [4]. Briefly, we first excluded samples with genotype completion rates < 95%, gender discrepancies, familial relationships, extreme heterozygosity rates (6 S.D. from the mean), or population stratification (> 6 S.D. from the mean on any one of the top ten principal components). Then, we excluded duplicate markers or SNPs with call rates < 95%, minor allele frequencies (MAFs) < 0.01 or Hardy–Weinberg equilibrium (HWE) *P* value < 1×10^{-7} in controls or HWE *P* value < 1×10^{-12} in cases. We phased the haplotypes with SHAPEIT v2 [20] and imputed with IMPUTE2 [21]. The 1000 Genomes Project (the Phase III integrated variant set release, across 2504 samples) was set as the reference.

Identification of NSCLC risk loci

To perform functional annotation, we first conducted genome-wide meta-analyses for NSCLC, lung AD, and SqCC, respectively, and then derived a set of lung cancer risk associated index variants including both 81 previously

Table 1 Demographic characteristics of lung AD, SqCC, and non-cancer controls included in this study

	NJMU project					
	Lung AD		Lung SqCC		Control	
	Number	%	Number	%	Number	%
Total	8762	100.0	3860	100.0	13 328	100.0
Age (mean±S.D.)	58.63±10.52		61.16±9.42		59.31±10.42	
Gender						
Male	4650	53.1	3470	89.9	8605	64.6
Female	4112	46.9	390	10.1	4723	35.4
Missing value	n/a	n/a	n/a	n/a	n/a	n/a
Smoking status						
Ever smoker	3364	38.4	3172	82.2	5606	42.1
Life-long non-smoker	5397	61.6	688	17.8	7720	57.9
Missing value	1	0.0	n/a	n/a	2	0.0
	TRICL-ILCCO OncoArray project					
	Lung AD		Lung SqCC		Control	
	Number	%	Number	%	Number	%
Total	6819	100.0	4490	100.0	14 027	100.0
Age (mean±S.D.)	63.57±10.80		64.84±9.62		61.77±10.29	
Gender						
Male	3626	53.2	3489	77.7	8638	61.6
Female	3192	46.8	1001	22.3	5386	38.4
Missing value	1	0.0	n/a	n/a	3	0.0
Smoking status						
Ever smoker	5771	84.6	4276	95.2	9339	66.6
Life-long non-smoker	974	14.3	156	3.5	4412	31.5
Missing value	74	1.1	58	1.3	276	1.9

Abbreviations: AD, adenocarcinoma; SqCC, squamous cell carcinoma.
n/a, no patients with missing information.

reported SNPs (Table S1) and those with a genome-wide significant P value $< 1 \times 10^{-6}$ in our overall NSCLC or histological meta-analyses. For 81 previously reported variants, index variants were defined as those met either of the following criteria: (1) $MAF \geq 0.01$; and (2) SNPs in weak linkage disequilibrium (LD, $r^2 < 0.6$) with each other. For other independent variants, index variants were defined if met one or more of the following criteria in our meta-analyses: (1) $MAF \geq 0.01$; (2) with a genome-wide significant P value $< 1 \times 10^{-6}$ in NSCLC, lung AD or SqCC meta-analysis; and (3) SNPs in weak LD with each other and previously reported variants ($r^2 < 0.01$). If one SNP identified in histology-specific meta-analysis also showed association with the other histology of lung cancer (AD or SqCC) ($P < 0.05$), it was considered as NSCLC related. Thus, 67 index variants derived from both 81 previously reported SNPs and those from our genome-wide meta-analyses were included in the following analysis. Then, we further mined SNPs in strong LD ($r^2 \geq 0.6$) with above defined index SNPs and physically within 500 kb upstream or downstream of the index SNP. All above defined index SNPs and associated SNPs in strong LD were considered as credible risk variants (CRVs) (Fig. 1A).

Identification of target genes for NSCLC risk loci by functional annotation

To define candidate target genes for lung cancer risk loci, we performed functional annotation with an extended *in silico* prediction of GWAS targets (INQUISIT) strategy [15] and calculated a score for each gene-CRV pair representing for the coding impact or potential regulatory mechanisms (proximal or distal gene regulation) by integrating multiple lines of evidence (Tables S2 and S3). Each target gene was scored based on distal regulation, proximal regulation, and coding sequence.

For the distally regulated gene, one score was given if: (1) the CRV was located in an enhancer element that was predicted to physically interact with the promoter of the target gene by FANTOM5 [13] or PreSTIGE [22]; (2) the enhancer element containing the CRV was overlapped with the transcription factor binding sites (TFBS) of one transcription factor (TF) (two scores were given if overlapped with more than one TF); (3) the CRV is an expression quantitative trait loci (eQTL) for that gene in the Genotype-Tissue Expression (GTEx), The Cancer Genome Atlas (TCGA) or Nanjing Lung Cancer Cohort (NJLCC) [23] databases; or (4) the gene was listed as a lung cancer somatic driver gene (except for driver gene enrichment analysis). Additionally, two scores were added if the CRV was also located in an enhancer element that physically interact with the promoter of that gene based on Hi-C experiment. However, the score was down-weighted

by multiplying by 0.05 if the target gene was separated from the CRV by topologically associating domain (TAD) boundaries, or down-weighted by multiplying by 0.1 if the gene was low expressed in the GTEx normal lung tissues (less than 1% samples with Transcripts Per Million (TPM) greater than 0.1), TCGA tumor/adjacent samples (less than 1% samples with Fragments Per Kilobase Million (FPKM) greater than 0.1) and NJLCC tumor/adjacent samples (less than 1% samples with TPM greater than 0.1).

Proximally regulated genes were defined as those with CRVs located 1 kb upstream and 100 bp downstream surrounding the transcription start sites (TSSs). One score was given if: (1) the gene was overlapped with promoter histone modification peaks (H3K4me3 or H3K9ac); (2) the gene was listed as a lung cancer somatic driver gene (except for driver gene enrichment analysis); (3) the histone modification peak that the CRV resided was also intersected with the TFBS of TFs; or (4) the CRV is an eQTL for that gene in GTEx, TCGA or NJLCC databases. The down-weighted criteria were the same as that for distally regulated genes.

CRVs located in the exonic regions were evaluated for their impact on the protein function. Combined Annotation Dependent Depletion (CADD) [24], Functional Analysis through Hidden Markov Models (FATHMM) [25], LRT [26], MutationTaster [27], PolyPhen-2 [28], and Sorting Tolerant from Intolerant (SIFT) [29] were used for the evaluation of missense variants. Other scoring strategy was the same as that for distally regulated genes.

Altogether, scores in the distal regulation category range from 0 to 7, in the promoter category from 0 to 4, and in the coding category from 0 to 3. We classified the candidate target genes into four levels based on the integrated scores: level 1 (distal score ≥ 4 , promoter score ≥ 3 , or coding score = 3), level 2 (distal score 1–3, promoter score 1–2, or coding score 1–2), level 3 (any score greater than 0), and level 4 (score 0). Genes categorized into level 1–2 were considered as potential targets and were included in the following analysis.

Expression quantitative trait loci analysis based on NJLCC and TCGA data

In addition to the GTEx project (v7), we also performed eQTL analysis with data from NJLCC and TCGA projects. The NJLCC [23] project included 90 Chinese NSCLC samples with available clinical information, gene expression data, copy number variation profiles and matched genotyping data. Gene expression data was available for 98 tumor/adjacent pairs. NJLCC samples were genotyped with whole-genome sequencing and the expression data was quantified by RNA-seq (Illumina HiSeq 1500 platform) [23]. A systematic quality control (QC) procedure was performed to filter out samples with missing




Fig. 1 Functional evaluation of 3064 lung cancer related credible risk variants (CRVs) defined in this study. (A) Flowchart for the study design. (B) Genomic distribution of 3064 lung cancer CRVs. The x-axis indicates the number of CRVs included in the genomic region type. (C) Enrichment of defined lung cancer CRVs (1020 for lung AD and 220 for SqCC) in histone modification peaks and DNase I hypersensitive sites. The x-axis indicates different types of modification peaks in lung cancer cell line types: A549, lung AD cell line; NHLF, lung fibroblasts cell line; AG04450 and HPF, lung fibroblasts cell lines; Lung, normal lung tissue. (D) Enrichment of defined lung cancer CRVs (1020 for lung AD and 220 for SqCC) in transcriptional factor binding sites. The x-axis indicates binding sites of different transcriptional factors. IMR90, lung fibroblasts cell line.

genotypes and duplicates. Principal component analysis (PCA) was also performed. Finally, all 90 NJLCC samples (55 lung ADs and 35 SqCCs) were included in the eQTL analysis.

Similarly, the TCGA project included 106 NSCLC samples with matched clinical information, gene expression data, copy number variation data, and genotyping data. TCGA samples were genotyped using Affymetrix Genome-Wide Human SNP Array 6.0 and the data was downloaded from the TCGA Firehose at the MIT Broad Institute. The RNA-seq (Illumina) based expression data of 106 TCGA matched adjacent normal samples was quantified by FPKM and obtained from the UCSC Xena website. For the genotyping data, we also performed a systematic QC procedure and PCA, and 3 TCGA samples with Asian ancestry were removed. As a result, 103 TCGA samples (55 lung ADs and 48 SqCCs) remained in the following analysis.

For eQTL analysis, we performed a linear regression using the R package Matrix eQTL [30] with default parameters. We set gene expression as the outcome, and SNP genotype as the covariate of interest with adjustment for age, gender, smoking status, the top ten principal components, and somatic copy number status.

Functional enrichment analysis of defined CRVs

To investigate the enrichment or depletion in chromatin modification peaks, we estimated the distribution of above CRVs in active promoter and enhancer regions identified in normal lung tissues, lung fibroblasts (NHLF), and lung cancer (A549) cell lines by using Variant Set Enrichment (VSE) [31]. The same analysis was performed in three lung fibroblasts (IMR90, HPF, and AG04450) and A549 cell lines to evaluate the overrepresentation of CRVs in DNase I hypersensitive sites (DHS) regions or TFBS. All the histone modification peaks of promoter and enhancer marks (H3K4me3, H3K9ac, H3K4me1, and K3K27ac), DHS, and TFBS data were downloaded from the UCSC Genome Browser.

Gene-based analysis

We performed gene-based analysis with genome-wide gene-based association study (GWAS) in MAGMA [32]. The *P* values from the GWAS meta-analyses for lung cancer, lung AD, and SqCC were used as input, and all 19 427 protein-coding genes from the NCBI 37.3 gene definitions were used as the basis for GWAS. We annotated all SNPs in our genome-wide meta-analyses to above genes, resulting in 18 233, 18 233, and 18 232 protein-coding genes that were represented by at least one SNP in the NSCLC, lung AD or SqCC meta-analyses, respectively. Genes with Benjamini-Hochberg (BH) adjusted *P* value < 0.05 were considered as significant.

Driver gene enrichment analysis

A gene was considered as lung cancer somatic driver gene if met one of the following criteria: (1) the gene was included in the COSMIC Cancer Gene Census (v78) and showed evidence to be lung cancer related [33]; (2) the gene was categorized as lung cancer-related mutational drivers, somatic copy number alteration (SCNA) drivers, or fusion drivers in the IntOGen database [34]; or (3) the gene was identified as significantly mutated genes or SCNA-related genes in recent whole-genome or whole-exome sequencing studies [23,35–39]. Finally, we listed a total 374 coding genes and 4 non-coding genes as lung cancer somatic driver genes. To evaluate the enrichment of these genes in our defined lung cancer target genes, we first re-scored genes implicated by INQUISIT, and then examined the overlap between this list of drivers and the target genes with different levels of evidence and performed fisher exact test to obtain the significance. To avoid the bias of non-coding genes, only protein-coding genes were included in this analysis.

Pathway enrichment analysis

We performed pathway enrichment analysis on the above defined candidate target genes as well as genes identified by gene-based analysis to evaluate their potential function in the development of lung cancer. The analysis was conducted with the Reactome Pathway Database [40] using R package clusterProfiler [41] and pathways with BH adjusted *P* value < 0.05 were retained.

Gene-Set Enrichment Analysis (GSEA)

The immune infiltration proportions [42] and homologous recombination deficiency (HRD) [43] index of TCGA lung AD and lung SqCC samples were downloaded from previously published studies. We first calculated the correlation coefficients between the proportions of six types of immune cells (B cell, CD4 T cell, CD8 T cell, neutrophils, macrophages, and dendritic cells) or HRD index and the expression of all protein-coding genes. Then, a ranked list of correlation coefficient was analyzed by Gene-Set Enrichment Analysis (GSEA) with our predefined lung AD and SqCC genes. This analysis was performed with R package clusterProfiler [41].

Statistical analyses

Detailed description for the meta-analysis of GWAS data from Chinese and European populations was provided in our previous study [4]. Briefly, the association testing for each variant was performed using the SNPTEST software (v2.5.4) with adjustment for age, gender, and the principal components. Meta-analysis was performed with the fixed-

effects inverse variance-weighting approach by using METAL [44]. Genetic variant with $r^2 \geq 75\%$ or P value for Cochran's Q statistic $\leq 1.0 \times 10^{-4}$ was considered with a high degree of heterogeneity, and was excluded from further analysis [45,46]. The LD coefficients (R^2 and D') was calculated with plink(v1.9) and PriorityPruner, and the genotyping data of the East Asian and European populations from the 1000 Genomes Project (the Phase III integrated variant set release) were set as the reference. General analyses were performed with R software (version 3.5.1). All statistical tests were two-sided.

Results

Definition of credible risk variants for non-small cell lung cancer

We performed overall and histological GWAS meta-analyses (Fig. 1A, Table 1). To clarify potential functional signals, we first defined 67 index SNPs based on the following criteria: (1) 58 index SNPs represented for 81 previously reported SNPs ($r^2 \geq 0.6$) (Table S1); and (2) 9 independent index SNPs with a meta P value $< 1 \times 10^{-6}$ in our overall NSCLC or histological meta-analyses (Table S4). Of 9 SNPs with a meta P value $< 1 \times 10^{-6}$, two were located in previously reported loci but showed weak LD ($r^2 < 0.01$) with previously reported SNPs (6p22.1: rs1815741: OR = 0.86, 95% CI = 0.81–0.91, $P = 2.99 \times 10^{-7}$; 11q23.3: rs4938515: OR = 1.07, 95% CI = 1.04–1.10, $P = 3.46 \times 10^{-7}$), and the other seven SNPs included five for NSCLC (4p14: rs116205103: OR = 0.83, 95% CI = 0.77–0.89, $P = 1.82 \times 10^{-7}$; 15q24.1: rs76354137: OR = 0.92, 95% CI = 0.88–0.95, $P = 5.74 \times 10^{-7}$; 2q21.3: rs3217451: OR = 0.90, 95% CI = 0.87–0.94, $P = 7.35 \times 10^{-7}$; 4q27: rs35661893: OR = 0.93, 95% CI = 0.91–0.96, $P = 3.56 \times 10^{-6}$; 13q24: rs719739: OR = 0.94, 95% CI = 0.92–0.97, $P = 1.94 \times 10^{-5}$), one for AD (9q31.3: rs12006500: OR = 1.12, 95% CI = 1.07–1.16, $P = 8.43 \times 10^{-8}$), and one for SqCC (8p23.1: rs2945908: OR = 0.89, 95% CI = 0.85–0.93, $P = 7.92 \times 10^{-7}$) (Table S4, Fig. S1).

Then, we defined additional CRVs for further functional annotation (SNPs with $r^2 \geq 0.6$ with one of 67 independent index SNPs and within 500 kb upstream or downstream of the corresponding index SNPs). Finally, we identified 3064 CRVs in the following analysis, including 1842 for NSCLC, 1020 for AD and 220 for SqCC (Fig. 1A).

Enrichment analysis of NSCLC CRVs

Most of the defined CRVs were in the intronic (intronic and ncRNA intronic: 1489; 48.60%) or intergenic regions (intergenic, downstream and upstream: 1444; 47.13%)

(Fig. 1B). We systematically evaluated the enrichment of these variants in histone modification peaks. Interestingly, we observed a significant enrichment of NSCLC related CRVs in promoter-like (H3K4me3 and H3K9ac) and enhancer-like (H3K4me1 and H3K27ac) histone modification peaks in normal lung tissues, lung fibroblasts (NHLF) and lung cancer (A549) cell lines (Fig. 1C), and most (7/11) of the enrichment degrees were greater for lung AD related CRVs (Fig. 1C). Additionally, the defined CRVs were also enriched in DHS regions in lung fibroblasts (AG04450) and lung cancer (A549) cell lines (Fig. 1C).

Then, we conducted TF enrichment analysis and strong signals were observed for the binding sites of ATF3, POLR2A, TCF12, MAX, YY1, CTCF, and MAFK in lung fibroblasts (IMR90 and AG04450) and lung cancer (A549) cell lines at the significant level of $P_{BH} < 0.05$. Of these TFs, CTCF (HPF, AG04450, and IMR90), RAD21 (IMR90) and USF1 (A549) were special for lung AD while TCF12 (A549) and CREB1 (A549) were for lung SqCC (Fig. 1D).

Additionally, 22 of the 39 exonic variants were non-synonymous, including two nonsense and 20 missense variants (Table S5, Fig. 1B). The index SNP rs11571833 (K3326*, c.A9976T) in 13q13.1 was a nonsense variant in exon 27 of *BRCA2*. The T allele could significantly increase the risk of lung cancer (OR = 1.50, 95% CI = 1.26–1.78, $P = 4.63 \times 10^{-6}$). Of the missense variants, rs17121881 (c.T281A, I94N) in *AMICA1* was predicted with the highest CADD score (CADD score = 23.5) and could lead to an isoleucine-to-asparagine change. rs17121881 was in exon 3 of *AMICA1* and showed strong LD with the index SNP rs55768116 ($r^2 = 0.78$) in 11q23.3. The A allele of rs17121881 could significantly increase the risk of lung cancer (OR = 1.08, 95% CI = 1.05–1.11, $P = 2.10 \times 10^{-9}$) as well as reduce the expression of *AMICA1* (GTEx: $\beta = -0.10$, $P = 0.005$; NJLCC: $\beta = -0.18$, $P = 0.02$). Interestingly, *AMICA1* also showed a decreased expression in both lung AD and SqCC samples when compared to adjacent normal samples in TCGA (AD: $P = 1.03 \times 10^{-17}$; SqCC: $P = 7.75 \times 10^{-23}$) and NJLCC (AD: $P = 1.76 \times 10^{-18}$; SqCC: $P = 6.58 \times 10^{-18}$) data (Fig. S2), suggesting a tumor suppressor role during the development of lung cancer.

Systematic functional annotation of NSCLC CRVs

To link the candidate variants to genes, we then applied an extended INQUISIT functional annotation strategy and mapped CRVs to potential target genes by evaluating the impact on coding sequences, proximal promoter, and distal enhancer regulations (Fig. 1A). Among all 3064 CRVs, the coding impact evaluation strategy aligned CRVs to 25 genes, the proximal regulatory gene mapping strategy matched CRVs to 624 genes, and the distal regulatory gene mapping strategy annotated CRVs to 1014 genes (Table

S6). Above findings resulted in 1047 unique mapped genes, among which 803 genes categorized as levels 1 and 2 were considered as functional target genes and included in the following analysis (distal regulation strategy: 589 genes; proximal regulation strategy: 604 genes; coding impact strategy: 18 genes) (Fig. 2A). Of these 803 genes, 395 were implicated by at least two mapping strategies, and 13 were implicated by all three (Fig. 2B, Table S6). Additionally, 227 genes were implicated in lung AD samples while only 82 genes were in lung SqCC samples.

Of the newly identified genes, *CASP8* was in a locus defined in our previous study [4] and was implicated by all three mapping strategies. The index SNP rs3769821 at 2q33.1, located in the histone modification marks targeting both promoters and enhancers in A549 and NHLF cell types (Fig. 2C–2D), was confirmed as a *cis*-eQTL variant for *CASP8* in 383 GTEx lung tissues ($P = 1.09 \times 10^{-37}$) (Fig. 2E). Interestingly, we also identified a missense variant (rs3769823, c.41A > G, p.Lys14Arg), in strong LD ($r^2 = 1$) with rs3769821, that was located in the first exon of *CASP8* isoform 7 (Fig. 2D). This isoform was highly expressed in normal lung tissues and was found to be regulated by rs3769823 ($P = 2.39 \times 10^{-10}$) (Fig. 2F). Additionally, we identified *RAD52* as a lung SqCC related gene which was regulated by both distal and proximal elements (Fig. S3). rs11571376 (12p13.33) was located at the promoter region of *RAD52* and the C allele could significantly increase the risk of lung cancer (OR = 1.10, 95% CI = 1.05–1.14, $P = 2.27 \times 10^{-5}$). Interestingly, C allele of rs11571376 was also associated with the expression of *RAD52* in normal lung tissues ($\beta = 0.21$, $P = 2.30 \times 10^{-17}$), and the expression of *RAD52* was significantly elevated in lung SqCC samples (TCGA: $P = 1.71 \times 10^{-4}$; NJLCC: $P = 6.27 \times 10^{-5}$) (Fig. S3). For lung AD, we also identified a novel gene *LIME1* with the highest INQUISIT score. rs6122147, in strong LD with the index SNP rs41309931 ($r^2 = 0.98$) in 20q13.3, was located in a distal enhancer element that physically interacted with the promoter of *LIME1* in A549 cell line (Fig. S4A). The T allele of rs6122147 could significantly increase the risk of lung cancer (OR = 1.06, 95% CI = 1.02–1.11, $P = 4.42 \times 10^{-3}$) and decrease the expression of *LIME1* in normal lung tissues ($\beta = -0.14$, $P = 4.20 \times 10^{-4}$) (Fig. S4B).

Gene-based analysis and driver gene enrichment analysis

To estimate the aggregated association of lung cancer, we performed GWAS analysis using MAGMA and identified 154 lung cancer associated genes (Fig. 3A, Tables S7–S9), of which 62 have been implicated in previous functional annotation analysis (Fig. 2A). Of these 154 genes, 70 genes were specific for AD and 57 were specific for SqCC. When combined with 803 genes identified by

INQUISIT, we implicated a total of 894 susceptibility genes for lung cancer (Fig. 2A), of which 274 were specific for AD and 123 were for SqCC (Fig. 3B).

Then, we evaluated the association between our defined target genes and previously known somatic driver genes (Table S10). To avoid the bias of non-coding genes, only protein-coding genes were included in this analysis. Among the genes implicated by INQUISIT (levels 1–4), we observed an enrichment of our defined target genes in 374 established lung cancer somatic-driver genes (23 out of 374 genes, ER = 1.95, $P = 0.005$), including *EGFR*, *CDKN2A*, *CHEK2*, and *TP53BP1*. The enrichment degree increased with the level of evidence (level 1: ER = 14.05, $P = 6.90 \times 10^{-5}$; level 2: ER = 1.38, $P = 0.30$; level 3: ER = 2.22, $P = 0.06$; level 4: ER = 0.00, $P = 1.00$; $P_{\text{trend}} = 0.06$). Similar results were found when genes implicated by distal regulation (ER = 1.97, $P = 0.005$; $P_{\text{trend}} = 0.95$), proximal regulation (ER = 1.43, $P = 0.25$; $P_{\text{trend}} = 2.95 \times 10^{-8}$), and coding impact (ER = 4.64, $P = 0.08$; $P_{\text{trend}} = 0.13$) were included. For genes derived from gene-based analysis, we also observed a significant enrichment in lung cancer somatic-driver genes (ER = 4.48, $P = 3.87 \times 10^{-5}$). Additionally, four somatic drivers (*PTK6*, *CBL*, *MECOM*, and *SVEP1*) were implicated specially for lung AD (ER = 2.48, $P = 0.09$), but no lung SqCC somatic drivers were detected.

Pathway enrichment analysis

To further explore biological pathways involved in the process of lung tumorigenesis, we performed pathway enrichment analysis of our defined target genes. To avoid the influence of non-coding genes, we only included 592 protein-coding genes in this analysis. The result revealed the involvement of 29 pathways ($P_{\text{BH}} < 0.05$) in the development of NSCLC, including 20 pathways related to immune function, such as PD-1 signaling ($P = 1.09 \times 10^{-13}$) and interferon gamma signaling pathway ($P = 1.15 \times 10^{-10}$), and six pathways in the neuronal system related to nicotinic acetylcholine receptors, and three pathways in the DNA repair system (Fig. 3C, Table S11). We also performed the same analysis for lung AD and SqCC genes, and identified that lung AD related genes were specifically enriched in immune related pathways (Fig. 3D, Table S12), while lung SqCC genes were enriched in homologous recombination (HR)-related repair pathways (Fig. 3E, Table S13), suggesting diverse mechanisms underlying the development of lung AD and SqCC.

Above findings indicated the importance of immune function and HR repair in the carcinogenesis of lung cancer. Thus, we evaluated the association of defined lung cancer genes with immune infiltration proportions and HRD index in TCGA lung AD and SqCC samples. Interestingly, we identified that lung SqCC genes were




Fig. 2 Implicated lung cancer target genes by functional annotation. (A) Circos plot showing 803 implicated genes by distal mapping, promoter mapping and coding mapping strategies. Blue indicates the mapping strategy (from inside to outside: distal, promoter, and coding mapping) and red indicates if the implicated gene is a driver gene. (B) Venn diagram showing the number of overlapped genes implicated by distal mapping, promoter mapping, coding mapping strategies, and GWAS. (C) Detailed functional annotation results for three risk loci of lung cancer. The x-axis indicates the implicated genes, and y-axis indicates the annotation evidence types. (D) Genomic region of *CASP8* in 2q33.1. (E and F) eQTL analysis of two CRVs (rs3769821 and rs3769823) and *CASP8* expression in 383 GTEx lung tissues.




Fig. 3 Implicated lung cancer target genes by gene-based and pathway enrichment analyses. (A) Manhattan plot of the GWAS analysis for NSCLC meta-analysis. The y-axis shows the $-\log_{10}$ transformed two-tailed P value of each gene from a linear model, and chromosomal position is shown on the x-axis. (B) Venn diagram showing the overlap of genes implicated by INQUISIT and MAGMA in NSCLC, lung AD and SqCC. (C) Pathway enrichment analysis of all genes implicated by INQUISIT and GMAMA for NSCLC. (D) Pathway enrichment analysis of lung AD genes. (E) Pathway enrichment analysis of lung SqCC genes. (F) GSEA analysis of NSCLC, lung AD and SqCC genes with homologous recombination deficiency. (G) GSEA analysis of NSCLC, lung AD and SqCC genes with B cell proportion. (H) GSEA analysis of NSCLC, lung AD and SqCC genes with CD4 T cell proportion. (I) GSEA analysis of NSCLC, lung AD and SqCC genes with CD8 T cell proportion. (J) GSEA analysis of NSCLC, lung AD and SqCC genes with dendritic cell proportion.

overrepresented in HRD-related genes (NES = 1.33, $P = 0.05$) (Fig. 3F) while lung AD genes were significantly overrepresented in four types of immune cells-related genes (B cell: NES = 1.39, $P = 0.002$; CD4 T cell: NES = 1.32, $P = 0.01$; CD8 T cell: NES = 1.31, $P = 0.04$; neutrophil: NES = 1.19, $P = 0.10$; macrophage: NES = 1.02, $P = 0.44$; dendritic: NES = 1.46, $P = 0.002$) while lung SqCC genes not (B cell: NES = 1.22, $P = 0.15$; CD4 T cell: NES = 1.14, $P = 0.26$; CD8 T cell: NES = -1.06, $P = 0.29$; neutrophil: NES = 0.94, $P = 0.62$; macrophage: NES = -1.22, $P = 0.17$; dendritic: NES = 1.00, $P = 0.50$) (Fig. 3G–3J).

Discussion

In this study, we performed a combined strategy of large-scale genome-wide meta-analysis and functional annotation to identify biological significance of lung cancer susceptibility loci and implicated a total of 894 candidate target genes. These predisposition genes could modify the risk of lung cancer by both shared and histology-specific transcriptional (enhancers, promoters, and TF) or translational (missense and nonsense variants) regulations. Furthermore, pathway enrichment and GSEA analysis indicated the importance of immune and HR-related DNA repair during the carcinogenesis process of lung AD and SqCC. These findings provided both a rich set of plausible gene targets for further functional studies and novel insights into understanding the biological underpinnings underlying the development of different histology types of lung cancer.

Consistent with previous studies, NSCLC CRVs were primarily mapped to the non-coding regions and showed a strong enrichment in CREs such as enhancer elements and histone modification peaks, suggesting that these variants contributed to the development of NSCLC mainly through transcriptional regulation. Interestingly, TFBS enrichment analysis implicated some pathology-specific TFs. CREB1 (cyclic AMP response element binding protein) is a transcriptional coactivator which plays important roles in the differentiation of bronchial epithelial cells and is overexpressed in NSCLC samples [47]. Many studies have identified that CREB1 could be activated by nicotine exposure [48,49], and the activated CREB1 recruits additional transcriptional machinery elements and leads to tumorigenesis [49]. Thus, CREB1 could be a possible target for the pathobiological process of smoking induced lung SqCC. As a member of the basic helix–loop–helix leucine zipper family, USF1 (upstream transcription factor 1) functions as a cellular transcription factor [50] and regulates the expression of SP-A [51]. SP-A is a lung-specific gene, especially for type II cells which is the origin of lung AD [51]. Thus, USF1 may regulate the risk of lung AD by modifying the expression of SP-A. Although exact roles of these TFs in the susceptibility to lung cancer have

not been comprehensively studied, the overrepresented binding sites provides an improved understanding of the transcriptional regulation mechanism in NSCLC etiology.

In previous studies, the development of lung AD and SqCC were found to share many genetic factors [3,4]. However, in recent years, accumulating evidence suggested that these two types of lung cancer also had large discrepancy in terms of both germline variations and somatic alterations [18]. In this study, we identified a set of predisposition genes both shared by lung AD and SqCC and specific to each histology. One of the most interesting result is the identification of *CASP8* in 2q33.1, an NSCLC risk locus reported in our previous study [4]. *CASP8* encodes caspase 8, which is a multivalent controller of innate immune signaling and inhibits inflammasome activation in dendritic cells, interferon-regulatory factor 3 activation and pro-inflammatory cell death [52]. *CASP8* has been implicated as a susceptibility gene for multiple cancers except for lung cancer [53,54]. In this study, we identified that the expression of *CASP8* is regulated by both a *cis*-eQTL in the enhancer element and a missense variant in the major isoform, suggesting a potential joint modification mechanism by which the susceptibility variants affect NSCLC risk [55]. Additionally, we identified some pathologically specific genes, such as *LIME1* for AD and *RAD52* for SqCC. *LIME1* encodes a membrane raft-associated adaptor protein which is an organizer of immunoreceptor signaling [56] and involves in CD4 and CD8 coreceptor signaling [57]. Thus, we speculate that *LIME1* might regulate lung AD risk by modifying immune response. *RAD52* is a key member in HR repair [58], which functions in DNA repair during S phase of the cell cycle [59] and act as a regulator of genomic stability [60]. In this study, we identified that *RAD52* expression was elevated by *cis*-eQTLs in both proximal and distal regulatory elements in lung SqCC samples, suggesting a tumor-promoting role of *RAD52* in the development of lung SqCC [61]. Above results indicate an important role of immune response during lung AD carcinogenesis as well as HR deficiency during lung SqCC carcinogenesis.

Interestingly, pathway enrichment and GSEA analysis also provided evidence for the importance of immune system and HR-related DNA repair during the development of lung AD and SqCC. Tumor-prompting inflammation is defined as a tumor-enabling hallmark of cancer [62] and has previously been implicated in lung cancer [63,64]. Our recent work also provided evidence for the specific association of immune infiltration with lung AD, and identified that inflammatory microenvironments formed in the early stage of lung AD [23], suggesting that immune infiltration occurring in the initial stage is the major risk factor for lung AD. As an indication of genomic instability [65], elevated somatic HRD level has also been reported in lung SqCC [43]. The strong association between lung

SqCC susceptibility genes and HRD observed in this study provided additional evidence that the somatic differences may have genetic ancestry origins and could regulate lung SqCC risk. As cigarette smoking is the major causal factor for lung SqCC [66], we propose that the continuous exposure to tobacco may directly lead to an increased level of HRD [66], and finally lead to lung SqCC. Thus, the use of PD1/PD-L1 and PARP inhibitors, which target immune infiltration and HRD [67,68], implicate significant potential for the prevention of lung AD and SqCC.

However, the interpretation of our findings needs to be considered within the limitations of the study. First, the aggregation of susceptibility variants identified in both European and Chinese populations prevented us from capturing the genetic heterogeneity within different ethnic and individuals. Second, as the annotation data used in this study were obtained from different sources of tissues and cell types, further biological experiments are needed to elucidate the exact molecular mechanisms of these variants underlying the development of lung cancer.

In conclusion, by integrating GWAS information, in-house and publicly available biological data, we illustrate the molecular basis of both well-studied and newly identified lung cancer susceptibility loci and provide novel insights into the understanding of genetic heterogeneity between lung AD and SqCC, which may serve as guides for post-GWAS functional experiments and clinical drug target testing.

Acknowledgments

This study was supported by the Key International (Regional) Cooperative Research Project (No. 81820108028), the National Natural Science Foundation of China (Nos. 81521004, 81922061, 81973123, and 81803306), the Science Foundation for Distinguished Young Scholars of Jiangsu (No. BK20160046), and the Priority Academic Program for the Development of Jiangsu Higher Education Institutions (Public Health and Preventive Medicine). CARET is funded by the National Cancer Institute, National Institutes of Health of USA through grants U01-CA063673, U01-CA167462, and U01-CA167462.

Compliance with ethics guidelines

Na Qin, Yuancheng Li, Cheng Wang, Meng Zhu, Juncheng Dai, Tongtong Hong, Demetrius Albanes, Stephen Lam, Adonina Tardon, Chu Chen, Gary Goodman, Stig E. Bojesen, Maria Teresa Landi, Mattias Johansson, Angela Risch, H-Erich Wichmann, Heike Bickeboller, Gadi Rennert, Susanne Arnold, Paul Brennan, John K. Field, Sanjay Shete, Loic Le Marchand, Olle Melander, Hans Brunnstrom, Geoffrey Liu, Rayjean J. Hung, Angeline Andrew, Lambertus A. Kiemeny, Shan Zienolddiny, Kjell Grankvist, Mikael Johansson, Neil Caporaso, Penella Woll, Philip Lazarus, Matthew B. Schabath, Melinda C. Aldrich, Victoria L. Stevens, Guangfu Jin,

David C. Christiani, Zhibin Hu, Christopher I. Amos, Hongxia Ma, and Hongbing Shen declare that they have no conflict of interest. Informed consent was obtained from all the participants included in this study, and each study was approved by the corresponding institutional review board.

Electronic Supplementary Material Supplementary material is available in the online version of this article at <https://doi.org/10.1007/s11684-020-0779-4> and is accessible for authorized users.

References

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin* 2018; 68(6): 394–424
2. Alberg AJ, Brock MV, Ford JG, Samet JM, Spivack SD. Epidemiology of lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. *Chest* 2013; 143(5 Suppl): e1S–e29S
3. Bossé Y, Amos CI. A decade of GWAS results in lung cancer. *Cancer Epidemiol Biomarkers Prev* 2018; 27(4): 363–379
4. Dai J, Lv J, Zhu M, Wang Y, Qin N, Ma H, He YQ, Zhang R, Tan W, Fan J, Wang T, Zheng H, Sun Q, Wang L, Huang M, Ge Z, Yu C, Guo Y, Wang TM, Wang J, Xu L, Wu W, Chen L, Bian Z, Walters R, Millwood IY, Li XZ, Wang X, Hung RJ, Christiani DC, Chen H, Wang M, Wang C, Jiang Y, Chen K, Chen Z, Jin G, Wu T, Lin D, Hu Z, Amos CI, Wu C, Wei Q, Jia WH, Li L, Shen H. Identification of risk loci and a polygenic risk score for lung cancer: a large-scale prospective cohort study in Chinese populations. *Lancet Respir Med* 2019; 7(10): 881–891
5. Dai J, Shen W, Wen W, Chang J, Wang T, Chen H, Jin G, Ma H, Wu C, Li L, Song F, Zeng Y, Jiang Y, Chen J, Wang C, Zhu M, Zhou W, Du J, Xiang Y, Shu XO, Hu Z, Zhou W, Chen K, Xu J, Jia W, Lin D, Zheng W, Shen H. Estimation of heritability for nine common cancers using data from genome-wide association studies in Chinese population. *Int J Cancer* 2017; 140(2): 329–336
6. Sampson JN, Wheeler WA, Yeager M, Panagiotou O, Wang Z, Berndt SI, Lan Q, Abnet CC, Amundadottir LT, Figueroa JD, Landi MT, Mirabello L, Savage SA, Taylor PR, De Vivo I, McGlynn KA, Purdue MP, Rajaraman P, Adami HO, Ahlbom A, Albanes D, Amary MF, An SJ, Andersson U, Andriole G Jr, Andriulis IL, Angelucci E, Ansell SM, Arici C, Armstrong BK, Arslan AA, Austin MA, Baris D, Barkauskas DA, Bassig BA, Becker N, Benavente Y, Benhamou S, Berg C, Van Den Berg D, Bernstein L, Bertrand KA, Birmann BM, Black A, Boeing H, Boffetta P, Boutron-Ruault MC, Bracci PM, Brinton L, Brooks-Wilson AR, Bueno-de-Mesquita HB, Burdett L, Buring J, Butler MA, Cai Q, Cancel-Tassin G, Canzian F, Carrato A, Carreon T, Carta A, Chan JK, Chang ET, Chang GC, Chang IS, Chang J, Chang-Claude J, Chen CJ, Chen CY, Chen C, Chen CH, Chen C, Chen H, Chen K, Chen KY, Chen KC, Chen Y, Chen YH, Chen YS, Chen YM, Chien LH, Chirlaque MD, Choi JE, Choi YY, Chow WH, Chung CC, Clavel J, Clavel-Chapelon F, Cocco P, Colt JS, Comperat E, Conde L, Connors JM, Conti D, Cortessis VK, Cotterchio M, Cozen W,

- Crouch S, Crous-Bou M, Cussenot O, Davis FG, Ding T, Diver WR, Dorronsoro M, Dossus L, Duell EJ, Ennas MG, Erickson RL, Feychting M, Flanagan AM, Foretova L, Fraumeni JF Jr, Freedman ND, Beane Freeman LE, Fuchs C, Gago-Dominguez M, Gallinger S, Gao YT, Gapstur SM, Garcia-Closas M, Garcia-Closas R, Gascoyne RD, Gastier-Foster J, Gaudet MM, Gaziano JM, Giffen C, Giles GG, Giovannucci E, Glimelius B, Goggins M, Gokgoz N, Goldstein AM, Gorlick R, Gross M, Grubb R 3rd, Gu J, Guan P, Gunter M, Guo H, Habermann TM, Haiman CA, Halai D, Hallmans G, Hassan M, Hattinger C, He Q, He X, Helzlsouer K, Henderson B, Henriksson R, Hjalgrim H, Hoffman-Bolton J, Hohensee C, Holford TR, Holly EA, Hong YC, Hoover RN, Horn-Ross PL, Hosain GM, Hosgood HD 3rd, Hsiao CF, Hu N, Hu W, Hu Z, Huang MS, Huerta JM, Hung JY, Hutchinson A, Inskip PD, Jackson RD, Jacobs EJ, Jenab M, Jeon HS, Ji BT, Jin G, Jin L, Johansen C, Johnson A, Jung YJ, Kaaks R, Kaminen A, Kane E, Kang CH, Karagas MR, Kelly RS, Khaw KT, Kim C, Kim HN, Kim JH, Kim JS, Kim YH, Kim YT, Kim YC, Kitahara CM, Klein AP, Klein RJ, Kogevinas M, Kohno T, Kolonel LN, Kooperberg C, Krickler A, Krogh V, Kunitoh H, Kurtz RC, Kweon SS, LaCroix A, Lawrence C, Lecanda F, Lee VH, Li D, Li H, Li J, Li YJ, Li Y, Liao LM, Liebow M, Lightfoot T, Lim WY, Lin CC, Lin D, Lindstrom S, Linet MS, Link BK, Liu C, Liu J, Liu L, Ljungberg B, Lloreta J, Di Lollo S, Lu D, Lund E, Malats N, Mannisto S, Le Marchand L, Marina N, Masala G, Mastrangelo G, Matsuo K, Maynadie M, McKay J, McKean-Cowdin R, Melbye M, Melin BS, Michaud DS, Mitsudomi T, Monnereau A, Montalvan R, Moore LE, Mortensen LM, Nieters A, North KE, Novak AJ, Oberg AL, Offit K, Oh IJ, Olson SH, Palli D, Pao W, Park IK, Park JY, Park KH, Patino-Garcia A, Pavanello S, Peeters PH, Perng RP, Peters U, Petersen GM, Picci P, Pike MC, Porru S, Prescott J, Prokunina-Olsson L, Qian B, Qiao YL, Rais M, Riboli E, Riby J, Risch HA, Rizzato C, Rodabough R, Roman E, Roupert M, Ruder AM, Sanjose S, Scelo G, Schned A, Schumacher F, Schwartz K, Schwenn M, Scotlandi K, Seow A, Serra C, Serra M, Sesso HD, Setiawan VW, Severi G, Severson RK, Shanafelt TD, Shen H, Shen W, Shin MH, Shiraishi K, Shu XO, Siddiq A, Sierrasesumaga L, Sihoe AD, Skibola CF, Smith A, Smith MT, Southey MC, Spinelli JJ, Staines A, Stampfer M, Stern MC, Stevens VL, Stolzenberg-Solomon RS, Su J, Su WC, Sund M, Sung JS, Sung SW, Tan W, Tang W, Tardon A, Thomas D, Thompson CA, Tinker LF, Tirabosco R, Tjonneland A, Travis RC, Trichopoulos D, Tsai FY, Tsai YH, Tucker M, Turner J, Vajdic CM, Vermeulen RC, Villano DJ, Vineis P, Virtamo J, Visvanathan K, Wactawski-Wende J, Wang C, Wang CL, Wang JC, Wang J, Wei F, Weiderpass E, Weiner GJ, Weinstein S, Wentzensen N, White E, Witzig TE, Wolpin BM, Wong MP, Wu C, Wu G, Wu J, Wu T, Wu W, Wu X, Wu YL, Wunder JS, Xiang YB, Xu J, Xu P, Yang PC, Yang TY, Ye Y, Yin Z, Yokota J, Yoon HI, Yu CJ, Yu H, Yu K, Yuan JM, Zelenetz A, Zeleniuch-Jacquotte A, Zhang XC, Zhang Y, Zhao X, Zhao Z, Zheng H, Zheng T, Zheng W, Zhou B, Zhu M, Zucca M, Boca SM, Cerhan JR, Ferri GM, Hartge P, Hsiung CA, Magnani C, Miligi L, Morton LM, Smedby KE, Teras LR, Vijai J, Wang SS, Brennan P, Caporaso NE, Hunter DJ, Kraft P, Rothman N, Silverman DT, Slager SL, Chanock SJ, Chatterjee N. Analysis of heritability and shared heritability based on genome-wide association studies for thirteen cancer types. *J Natl Cancer Inst* 2015; 107(12): djv279
7. Freedman ML, Monteiro AN, Gayther SA, Coetzee GA, Risch A, Plass C, Casey G, De Biasi M, Carlson C, Duggan D, James M, Liu P, Tichelaar JW, Vikis HG, You M, Mills IG. Principles for the post-GWAS functional characterization of cancer risk loci. *Nat Genet* 2011; 43(6): 513–518
 8. Hindorf LA, Sethupathy P, Junkins HA, Ramos EM, Mehta JP, Collins FS, Manolio TA. Potential etiologic and functional implications of genome-wide association loci for human diseases and traits. *Proc Natl Acad Sci USA* 2009; 106(23): 9362–9367
 9. Garraway LA, Sellers WR. Lineage dependency and lineage-survival oncogenes in human cancer. *Nat Rev Cancer* 2006; 6(8): 593–602
 10. Sato M, Shames DS, Gazdar AF, Minna JD. A translational view of the molecular pathogenesis of lung cancer. *J Thorac Oncol* 2007; 2(4): 327–343
 11. Shen H, Zhu M, Wang C. Precision oncology of lung cancer: genetic and genomic differences in Chinese population. *NPJ Precis Oncol* 2019; 3(1): 14
 12. The ENCODE Project Consortium. The ENCODE (ENCyclopedia Of DNA Elements) Project. *Science* 2004; 306(5696): 636–640
 13. Andersson R, Gebhard C, Miguel-Escalada I, Hoof I, Bornholdt J, Boyd M, Chen Y, Zhao X, Schmidl C, Suzuki T, Ntini E, Arner E, Valen E, Li K, Schwarzfischer L, Glatz D, Raithe J, Lilje B, Rapin N, Bagger FO, Jorgensen M, Andersen PR, Bertin N, Rackham O, Burroughs AM, Baillie JK, Ishizu Y, Shimizu Y, Furuhashi E, Maeda S, Negishi Y, Mungall CJ, Meehan TF, Lassmann T, Itoh M, Kawaji H, Kondo N, Kawai J, Lennartsson A, Daub CO, Heutink P, Hume DA, Jensen TH, Suzuki H, Hayashizaki Y, Muller F, Forrest ARR, Carninci P, Rehli M, Sandelin A. An atlas of active enhancers across human cell types and tissues. *Nature* 2014; 507(7493): 455–461
 14. Roadmap Epigenomics C, Kundaje A, Meuleman W, Ernst J, Bilenky M, Yen A, Heravi-Moussavi A, Kheradpour P, Zhang Z, Wang J, Ziller MJ, Amin V, Whitaker JW, Schultz MD, Ward LD, Sarkar A, Quon G, Sandstrom RS, Eaton ML, Wu YC, Pfenning AR, Wang X, Claussnitzer M, Liu Y, Coarfà C, Harris RA, Shores N, Epstein CB, Gjoneska E, Leung D, Xie W, Hawkins RD, Lister R, Hong C, Gascard P, Mungall AJ, Moore R, Chuah E, Tam A, Canfield TK, Hansen RS, Kaul R, Sabo PJ, Bansal MS, Carles A, Dixon JR, Farh KH, Feizi S, Karlic R, Kim AR, Kulkarni A, Li D, Lowdon R, Elliott G, Mercer TR, Neph SJ, Onuchic V, Polak P, Rajagopal N, Ray P, Sallari RC, Siebenthal KT, Sinnott-Armstrong NA, Stevens M, Thurman RE, Wu J, Zhang B, Zhou X, Beaudet AE, Boyer LA, De Jager PL, Farnham PJ, Fisher SJ, Haussler D, Jones SJ, Li W, Marra MA, McManus MT, Sunyaev S, Thomson JA, Tlsty TD, Tsai LH, Wang W, Waterland RA, Zhang MQ, Chadwick LH, Bernstein BE, Costello JF, Ecker JR, Hirst M, Meissner A, Milosavljevic A, Ren B, Stamatoyannopoulos JA, Wang T, Kellis M. Integrative analysis of 111 reference human epigenomes. *Nature* 2015; 518(7539): 317–330
 15. Michailidou K, Lindstrom S, Dennis J, Beesley J, Hui S, Kar S, Lemaçon A, Soucy P, Glubb D, Rostamianfar A, Bolla MK, Wang Q, Tyrer J, Dicks E, Lee A, Wang Z, Allen J, Keeman R, Eilber U, French JD, Qing Chen X, Fachal L, McCue K, McCart Reed AE, Ghossein M, Carroll JS, Jiang X, Finucane H, Adams M, Adank MA, Ahsan H, Aittomäki K, Anton-Culver H, Antonenkova NN, Arndt V, Aronson KJ, Arun B, Auer PL, Bacot F, Barrdahl M, Baynes C, Beckmann MW, Behrens S, Benitez J, Bermisheva M, Bernstein L, Blomqvist C, Bogdanova NV, Bojesen SE, Bonanni B, Borresen-Dale AL, Brand JS, Brauch H, Brennan P, Brenner H, Brinton L, Broberg P, Brock IW, Broeks A, Brooks-Wilson A,

- Brucker SY, Bruning T, Burwinkel B, Butterbach K, Cai Q, Cai H, Caldes T, Canzian F, Carracedo A, Carter BD, Castelao JE, Chan TL, David Cheng TY, Seng Chia K, Choi JY, Christiansen H, Clarke CL, Collaborators N, Collee M, Conroy DM, Cordina-Duverger E, Cornelissen S, Cox DG, Cox A, Cross SS, Cunningham JM, Czene K, Daly MB, Devilee P, Doheny KF, Dork T, Dos-Santos-Silva I, Dumont M, Durcan L, Dwek M, Eccles DM, Ekici AB, Eliassen AH, Ellberg C, Elvira M, Engel C, Eriksson M, Fasching PA, Figueroa J, Flesch-Janys D, Fletcher O, Flyger H, Fritschi L, Gaborieau V, Gabrielson M, Gago-Dominguez M, Gao YT, Gapstur SM, Garcia-Saenz JA, Gaudet MM, Georgoulas V, Giles GG, Glendon G, Goldberg MS, Goldgar DE, Gonzalez-Neira A, Grenaker Alnaes GI, Grip M, Gronwald J, Grundy A, Guenel P, Haeberle L, Hahnen E, Haiman CA, Hakansson N, Hamann U, Hamel N, Hankinson S, Harrington P, Hart SN, Hartikainen JM, Hartman M, Hein A, Heyworth J, Hicks B, Hillemanns P, Ho DN, Hollestelle A, Hooning MJ, Hoover RN, Hopper JL, Hou MF, Hsiung CN, Huang G, Humphreys K, Ishiguro J, Ito H, Iwasaki M, Iwata H, Jakubowska A, Janni W, John EM, Johnson N, Jones K, Jones M, Jukkola-Vuorinen A, Kaaks R, Kabisch M, Kaczmarek K, Kang D, Kasuga Y, Kerin MJ, Khan S, Khusnutdinova E, Kiiski JI, Kim SW, Knight JA, Kosma VM, Kristensen VN, Kruger U, Kwong A, Lambrechts D, Le Marchand L, Lee E, Lee MH, Lee JW, Neng Lee C, Lejbkowitz F, Li J, Lilyquist J, Lindblom A, Lissowska J, Lo WY, Loibl S, Long J, Lophatananon A, Lubinski J, Luccarini C, Lux MP, Ma ESK, MacInnis RJ, Maishman T, Makalic E, Malone KE, Kostovska IM, Mannermaa A, Manoukian S, Manson JE, Margolin S, Mariapun S, Martinez ME, Matsuo K, Mavroudis D, McKay J, McLean C, Meijers-Heijboer H, Meindl A, Menendez P, Menon U, Meyer J, Miao H, Miller N, Taib NAM, Muir K, Mulligan AM, Mulot C, Neuhausen SL, Nevanlinna H, Neven P, Nielsen SF, Noh DY, Nordestgaard BG, Norman A, Olopade OI, Olson JE, Olsson H, Olswold C, Orr N, Pankratz VS, Park SK, Park-Simon TW, Lloyd R, Perez JIA, Peterlongo P, Peto J, Phillips KA, Pinchev M, Plaseska-Karanfilska D, Prentice R, Presneau N, Prokofyeva D, Pugh E, Pylkas K, Rack B, Radice P, Rahman N, Rennert G, Rennert HS, Rhenius V, Romero A, Romm J, Ruddy KJ, Rudiger T, Rudolph A, Ruebner M, Rutgers EJT, Saloustros E, Sandler DP, Sangrajrang S, Sawyer EJ, Schmidt DF, Schmutzler RK, Schneeweiss A, Schoemaker MJ, Schumacher F, Schurmann P, Scott RJ, Scott C, Seal S, Seynaeve C, Shah M, Sharma P, Shen CY, Sheng G, Sherman ME, Shrubsole MJ, Shu XO, Smeets A, Sohn C, Southey MC, Spinelli JJ, Stegmaier C, Stewart-Brown S, Stone J, Stram DO, Surowy H, Swerdlow A, Tamimi R, Taylor JA, Tengstrom M, Teo SH, Beth Terry M, Tessier DC, Thanasitthichai S, Thone K, Tollenaar R, Tomlinson I, Tong L, Torres D, Truong T, Tseng CC, Tsugane S, Ulmer HU, Ursin G, Untch M, Vachon C, van Asperen CJ, Van Den Berg D, van den Ouweland AMW, van der Kolk L, van der Luijt RB, Vincent D, Vollenweider J, Waisfisz Q, Wang-Gohrke S, Weinberg CR, Wendt C, Whittemore AS, Wildiers H, Willett W, Winqvist R, Wolk A, Wu AH, Xia L, Yamaji T, Yang XR, Har Yip C, Yoo KY, Yu JC, Zheng W, Zheng Y, Zhu B, Ziogas A, Ziv E; ABCTB Investigators; ConFab/AOCS Investigators, Lakhani SR, Antoniou AC, Droit A, Andrulis IL, Amos CI, Couch FJ, Pharoah PDP, Chang-Claude J, Hall P, Hunter DJ, Milne RL, Garcia-Closas M, Schmidt MK, Chanock SJ, Dunning AM, Edwards SL, Bader GD, Chenevix-Trench G, Simard J, Kraft P, Easton DF. Association analysis identifies 65 new breast cancer risk loci. *Nature* 2017; 551(7678): 92–94
16. Jiang X, Finucane HK, Schumacher FR, Schmit SL, Tyrer JP, Han Y, Michailidou K, Lesueur C, Kuchenbaecker KB, Dennis J, Conti DV, Casey G, Gaudet MM, Huyghe JR, Albanes D, Aldrich MC, Andrew AS, Andrulis IL, Anton-Culver H, Antoniou AC, Antonenkova NN, Arnold SM, Aronson KJ, Arun BK, Bandera EV, Barkardottir RB, Barnes DR, Batra J, Beckmann MW, Benitez J, Benlloch S, Berchuck A, Berndt SI, Bickeboller H, Bien SA, Blomqvist C, Boccia S, Bogdanova NV, Bojesen SE, Bolla MK, Brauch H, Brenner H, Brenton JD, Brook MN, Brunet J, Brunnstrom H, Buchanan DD, Burwinkel B, Butzow R, Cadoni G, Caldes T, Caligo MA, Campbell I, Campbell PT, Cancel-Tassin G, Cannon-Albright L, Campa D, Caporaso N, Carvalho AL, Chan AT, Chang-Claude J, Chanock SJ, Chen C, Christiani DC, Claes KBM, Claessens F, Clements J, Collee JM, Correa MC, Couch FJ, Cox A, Cunningham JM, Cybulski C, Czene K, Daly MB, deFazio A, Devilee P, Diez O, Gago-Dominguez M, Donovan JL, Dork T, Duell EJ, Dunning AM, Dwek M, Eccles DM, Edlund CK, Edwards DRV, Ellberg C, Evans DG, Fasching PA, Ferris RL, Liloglou T, Figueiredo JC, Fletcher O, Fortner RT, Fostira F, Franceschi S, Friedman E, Gallinger SJ, Ganz PA, Garber J, Garcia-Saenz JA, Gayther SA, Giles GG, Godwin AK, Goldberg MS, Goldgar DE, Goode EL, Goodman MT, Goodman G, Grankvist K, Greene MH, Gronberg H, Gronwald J, Guenel P, Hakansson N, Hall P, Hamann U, Hamdy FC, Hamilton RJ, Hampe J, Haugen A, Heitz F, Herrero R, Hillemanns P, Hoffmeister M, Hogdall E, Hong YC, Hopper JL, Houlston R, Hulick PJ, Hunter DJ, Huntsman DG, Idos G, Imyanitov EN, Ingles SA, Isaacs C, Jakubowska A, James P, Jenkins MA, Johansson M, Johansson M, John EM, Joshi AD, Kaneva R, Karlan BY, Kelemen LE, Kuhl T, Khaw KT, Khusnutdinova E, Kibel AS, Kiemeny LA, Kim J, Kjaer SK, Knight JA, Kogevinas M, Kote-Jarai Z, Koutros S, Kristensen VN, Kupryjanczyk J, Lacko M, Lam S, Lambrechts D, Landi MT, Lazarus P, Le ND, Lee E, Lejbkowitz F, Lenz HJ, Leslie G, Lessel D, Lester J, Levine DA, Li L, Li CI, Lindblom A, Lindor NM, Liu G, Loupakis F, Lubinski J, Maehle L, Maier C, Mannermaa A, Marchand LL, Margolin S, May T, McGuffog L, Meindl A, Middha P, Miller A, Milne RL, MacInnis RJ, Modugno F, Montagna M, Moreno V, Moysich KB, Mucci L, Muir K, Mulligan AM, Nathanson KL, Neal DE, Ness AR, Neuhausen SL, Nevanlinna H, Newcomb PA, Newcomb LF, Nielsen FC, Nikitina-Zake L, Nordestgaard BG, Nussbaum RL, Offit K, Olah E, Olama AAA, Olopade OI, Olshan AF, Olsson H, Osorio A, Pandha H, Park JY, Pashayan N, Parsons MT, Pejovic T, Penney KL, Peters WHM, Phelan CM, Phipps AI, Plaseska-Karanfilska D, Pring M, Prokofyeva D, Radice P, Stefansson K, Ramus SJ, Raskin L, Rennett G, Rennett HS, van Rensburg EJ, Riggan MJ, Risch HA, Risch A, Roobol MJ, Rosenstein BS, Rossing MA, De Ruyc K, Saloustros E, Sandler DP, Sawyer EJ, Schabath MB, Schleutker J, Schmidt MK, Setiawan VW, Shen H, Siegel EM, Sieh W, Singer CF, Slattery ML, Sorensen KD, Southey MC, Spurdle AB, Stanford JL, Stevens VL, Stintzing S, Stone J, Sundfeldt K, Sutphen R, Swerdlow AJ, Tajara EH, Tangen CM, Tardon A, Taylor JA, Teare MD, Teixeira MR, Terry MB, Terry KL, Thibodeau SN, Thomassen M, Bjorge L, Tischkowitz M, Toland AE, Torres D, Townsend PA, Travis RC, Tung N, Tworoger SS, Ulrich CM, Usmani N, Vachon CM, Van Nieuwenhuysen E, Vega A, Aguado-Barrera ME, Wang Q,

- Webb PM, Weinberg CR, Weinstein S, Weissler MC, Weitzel JN, West CML, White E, Whittemore AS, Wichmann HE, Wiklund F, Winqvist R, Wolk A, Woll P, Woods M, Wu AH, Wu X, Yannoukakos D, Zheng W, Zienolddiny S, Ziogas A, Zorn KK, Lane JM, Saxena R, Thomas D, Hung RJ, Diergaarde B, McKay J, Peters U, Hsu L, Garcia-Closas M, Eeles RA, Chenevix-Trench G, Brennan PJ, Haiman CA, Simard J, Easton DF, Gruber SB, Pharoah PDP, Price AL, Pasaniuc B, Amos CI, Kraft P, Lindström S. Shared heritability and functional enrichment across six solid cancers. *Nat Commun* 2019; 10(1): 431
17. Farh KK, Marson A, Zhu J, Kleinewietfeld M, Housley WJ, Beik S, Shores N, Whitton H, Ryan RJ, Shishkin AA, Hatan M, Carrasco-Alfonso MJ, Mayer D, Luckey CJ, Patsopoulos NA, De Jager PL, Kuchroo VK, Epstein CB, Daly MJ, Hafler DA, Bernstein BE. Genetic and epigenetic fine mapping of causal autoimmune disease variants. *Nature* 2015; 518(7539): 337–343
 18. McKay JD, Hung RJ, Han Y, Zong X, Carreras-Torres R, Christiani DC, Caporaso NE, Johansson M, Xiao X, Li Y, Byun J, Dunning A, Pooley KA, Qian DC, Ji X, Liu G, Timofeeva MN, Bojesen SE, Wu X, Le Marchand L, Albanes D, Bickeboller H, Aldrich MC, Bush WS, Tardon A, Rennert G, Teare MD, Field JK, Kiemeny LA, Lazarus P, Haugen A, Lam S, Schabath MB, Andrew AS, Shen H, Hong YC, Yuan JM, Bertazzi PA, Pesatori AC, Ye Y, Diao N, Su L, Zhang R, Brhane Y, Leigh N, Johansen JS, Mellemegaard A, Saliba W, Haiman CA, Wilkens LR, Fernandez-Somoano A, Fernandez-Tardon G, van der Heijden HFM, Kim JH, Dai J, Hu Z, Davies MPA, Marcus MW, Brunnstrom H, Manjer J, Melander O, Muller DC, Overvad K, Trichopoulou A, Tumino R, Doherty JA, Barnett MP, Chen C, Goodman GE, Cox A, Taylor F, Woll P, Bruske I, Wichmann HE, Manz J, Muley TR, Risch A, Rosenberger A, Grankvist K, Johansson M, Shepherd FA, Tsao MS, Arnold SM, Haura EB, Bolca C, Holcatova I, Janout V, Kontic M, Lissowska J, Mukeria A, Ognjanovic S, Orłowski TM, Scelo G, Swiatkowska B, Zaridze D, Bakke P, Skaug V, Zienolddiny S, Duell EJ, Butler LM, Koh WP, Gao YT, Houlston RS, McLaughlin J, Stevens VL, Joubert P, Lamontagne M, Nickle DC, Obeidat M, Timens W, Zhu B, Song L, Kachuri L, Artigas MS, Tobin MD, Wain LV; SpiroMeta Consortium, Rafnar T, Thorgeirsson TE, Reginsson GW, Stefansson K, Hancock DB, Bierut LJ, Spitz MR, Gaddis NC, Lutz SM, Gu F, Johnson EO, Kamal A, Pikielny C, Zhu D, Lindström S, Jiang X, Tyndale RF, Chenevix-Trench G, Beesley J, Bossé Y, Chanock S, Brennan P, Landi MT, Amos CI. Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes. *Nat Genet* 2017; 49(7): 1126–1132
 19. Hu Z, Wu C, Shi Y, Guo H, Zhao X, Yin Z, Yang L, Dai J, Hu L, Tan W, Li Z, Deng Q, Wang J, Wu W, Jin G, Jiang Y, Yu D, Zhou G, Chen H, Guan P, Chen Y, Shu Y, Xu L, Liu X, Liu L, Xu P, Han B, Bai C, Zhao Y, Zhang H, Yan Y, Ma H, Chen J, Chu M, Lu F, Zhang Z, Chen F, Wang X, Jin L, Lu J, Zhou B, Lu D, Wu T, Lin D, Shen H. A genome-wide association study identifies two new lung cancer susceptibility loci at 13q12.12 and 22q12.2 in Han Chinese. *Nat Genet* 2011; 43(8): 792–796
 20. Delaneau O, Marchini J, Zagury JF. A linear complexity phasing method for thousands of genomes. *Nat Methods* 2012; 9(2): 179–181
 21. Howie BN, Donnelly P, Marchini J. A flexible and accurate genotype imputation method for the next generation of genome-wide association studies. *PLoS Genet* 2009; 5(6): e1000529
 22. Corradin O, Saiakhova A, Akhtar-Zaidi B, Myeroff L, Willis J, Cowper-Sal·lari R, Lupien M, Markowitz S, Scacheri PC. Combinatorial effects of multiple enhancer variants in linkage disequilibrium dictate levels of gene expression to confer susceptibility to common traits. *Genome Res* 2014; 24(1): 1–13
 23. Wang C, Yin R, Dai J, Gu Y, Cui S, Ma H, Zhang Z, Huang J, Qin N, Jiang T, Geng L, Zhu M, Pu Z, Du F, Wang Y, Yang J, Chen L, Wang Q, Jiang Y, Dong L, Yao Y, Jin G, Hu Z, Jiang L, Xu L, Shen H. Whole-genome sequencing reveals genomic signatures associated with the inflammatory microenvironments in Chinese NSCLC patients. *Nat Commun* 2018; 9(1): 2054
 24. Kircher M, Witten DM, Jain P, O’Roak BJ, Cooper GM, Shendure J. A general framework for estimating the relative pathogenicity of human genetic variants. *Nat Genet* 2014; 46(3): 310–315
 25. Shihab HA, Gough J, Cooper DN, Stenson PD, Barker GL, Edwards KJ, Day IN, Gaunt TR. Predicting the functional, molecular, and phenotypic consequences of amino acid substitutions using hidden Markov models. *Hum Mutat* 2013; 34(1): 57–65
 26. Chun S, Fay JC. Identification of deleterious mutations within three human genomes. *Genome Res* 2009; 19(9): 1553–1561
 27. Schwarz JM, Rodelsperger C, Schuelke M, Seelow D. MutationTaster evaluates disease-causing potential of sequence alterations. *Nat Methods* 2010; 7(8): 575–576
 28. Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, Kondrashov AS, Sunyaev SR. A method and server for predicting damaging missense mutations. *Nat Methods* 2010; 7(4): 248–249
 29. Kumar P, Henikoff S, Ng PC. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. *Nat Protoc* 2009; 4(7): 1073–1081
 30. Shabalin AA. Matrix eQTL: ultra fast eQTL analysis via large matrix operations. *Bioinformatics* 2012; 28(10): 1353–1358
 31. Cowper-Sal·lari R, Zhang X, Wright JB, Bailey SD, Cole MD, Eeckhoutte J, Moore JH, Lupien M. Breast cancer risk-associated SNPs modulate the affinity of chromatin for FOXA1 and alter gene expression. *Nat Genet* 2012; 44(11): 1191–1198
 32. de Leeuw CA, Mooij JM, Heskes T, Posthuma D. MAGMA: generalized gene-set analysis of GWAS data. *PLOS Comput Biol* 2015; 11(4): e1004219
 33. Futreal PA, Coin L, Marshall M, Down T, Hubbard T, Wooster R, Rahman N, Stratton MR. A census of human cancer genes. *Nat Rev Cancer* 2004; 4(3): 177–183
 34. Gonzalez-Perez A, Perez-Llamas C, Deu-Pons J, Tamborero D, Schroeder MP, Jene-Sanz A, Santos A, Lopez-Bigas N. IntOGen-mutations identifies cancer drivers across tumor types. *Nat Methods* 2013; 10(11): 1081–1082
 35. Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. *Nature* 2012; 489(7417): 519–525
 36. Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. *Nature* 2014; 511(7511): 543–550
 37. Campbell JD, Alexandrov A, Kim J, Wala J, Berger AH, Pedamallu CS, Shukla SA, Guo G, Brooks AN, Murray BA, Imielinski M, Hu X, Ling S, Akbani R, Rosenberg M, Cibulskis C, Ramachandran A, Collisson EA, Kwiatkowski DJ, Lawrence MS, Weinstein JN,

- Verhaak RG, Wu CJ, Hammerman PS, Cherniack AD, Getz G; Cancer Genome Atlas Research Network, Artyomov MN, Schreiber R, Govindan R, Meyerson M. Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas. *Nat Genet* 2016; 48(6): 607–616
38. Zhang XC, Wang J, Shao GG, Wang Q, Qu X, Wang B, Moy C, Fan Y, Albertyn Z, Huang X, Zhang J, Qiu Y, Platero S, Lorenzi MV, Zudaire E, Yang J, Cheng Y, Xu L, Wu YL. Comprehensive genomic and immunological characterization of Chinese non-small cell lung cancer patients. *Nat Commun* 2019; 10(1): 1772
39. Imielinski M, Berger AH, Hammerman PS, Hernandez B, Pugh TJ, Hodi E, Cho J, Suh J, Capelletti M, Sivachenko A, Sougnez C, Auclair D, Lawrence MS, Stojanov P, Cibulskis K, Choi K, de Waal L, Sharifnia T, Brooks A, Greulich H, Banerji S, Zander T, Seidel D, Leenders F, Ansen S, Ludwig C, Engel-Riedel W, Stoelben E, Wolf J, Goparju C, Thompson K, Winckler W, Kwiatkowski D, Johnson BE, Janne PA, Miller VA, Pao W, Travis WD, Pass HI, Gabriel SB, Lander ES, Thomas RK, Garraway LA, Getz G, Meyerson M. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. *Cell* 2012; 150(6): 1107–1120
40. Croft D, O'Kelly G, Wu G, Haw R, Gillespie M, Matthews L, Caudy M, Garapati P, Gopinath G, Jassal B, Jupe S, Kalatskaya I, Mahajan S, May B, Ndegwa N, Schmidt E, Shamovsky V, Yung C, Birney E, Hermjakob H, D'Eustachio P, Stein L. Reactome: a database of reactions, pathways and biological processes. *Nucleic Acids Res* 2011; 39(Database issue): D691–D697
41. Yu G, Wang LG, Han Y, He QY. clusterProfiler: an R package for comparing biological themes among gene clusters. *OMICS* 2012; 16(5): 284–287
42. Thorsson V, Gibbs DL, Brown SD, Wolf D, Bortone DS, Ou Yang TH, Porta-Pardo E, Gao GF, Plaisier CL, Eddy JA, Ziv E, Culhane AC, Paull EO, Sivakumar IKA, Gentles AJ, Malhotra R, Farshidfar F, Colaprico A, Parker JS, Mose LE, Vo NS, Liu J, Liu Y, Rader J, Dhankani V, Reynolds SM, Bowlby R, Califano A, Cherniack AD, Anastassiou D, Bedognetti D, Mokrab Y, Newman AM, Rao A, Chen K, Krasnitz A, Hu H, Malta TM, Noushmehr H, Pedamallu CS, Bullman S, Ojesina AI, Lamb A, Zhou W, Shen H, Choueiri TK, Weinstein JN, Guinney J, Saltz J, Holt RA, Rabkin CS; Cancer Genome Atlas Research Network, Lazar AJ, Serody JS, Demicco EG, Disis ML, Vincent BG, Shmulevich I. The immune landscape of cancer. *Immunity* 2018; 48(4): 812–830.e14
43. Knijnenburg TA, Wang L, Zimmermann MT, Chambwe N, Gao GF, Cherniack AD, Fan H, Shen H, Way GP, Greene CS, Liu Y, Akbani R, Feng B, Donehower LA, Miller C, Shen Y, Karimi M, Chen H, Kim P, Jia P, Shinbrot E, Zhang S, Liu J, Hu H, Bailey MH, Yau C, Wolf D, Zhao Z, Weinstein JN, Li L, Ding L, Mills GB, Laird PW, Wheeler DA, Shmulevich I; Cancer Genome Atlas Research Network, Monnat RJ Jr, Xiao Y, Wang C. Genomic and molecular landscape of DNA damage repair deficiency across the cancer genome atlas. *Cell Rep* 2018; 23(1): 239–254.e6
44. Willer CJ, Li Y, Abecasis GR. METAL: fast and efficient meta-analysis of genomewide association scans. *Bioinformatics* 2010; 26(17): 2190–2191
45. Liu JZ, van Sommeren S, Huang H, Ng SC, Alberts R, Takahashi A, Ripke S, Lee JC, Jostins L, Shah T, Abedean S, Cheon JH, Cho J, Dayani NE, Franke L, Fuyuno Y, Hart A, Juyal RC, Juyal G, Kim WH, Morris AP, Poustchi H, Newman WG, Midha V, Orchard TR, Vahedi H, Sood A, Sung JY, Malekzadeh R, Westra HJ, Yamazaki K, Yang SK; International Multiple Sclerosis Genetics Consortium; International IBD Genetics Consortium, Barrett JC, Alizadeh BZ, Parkes M, Bk T, Daly MJ, Kubo M, Anderson CA, Weersma RK. Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations. *Nat Genet* 2015; 47(9): 979–986
46. Surendran P, Drenos F, Young R, Warren H, Cook JP, Manning AK, Grarup N, Sim X, Barnes DR, Witkowska K, Staley JR, Tragante V, Tukiainen T, Yaghootkar H, Masca N, Freitag DF, Ferreira T, Giannakopoulou O, Tinker A, Harakalova M, Mihailov E, Liu C, Kraja AT, Fallgaard Nielsen S, Rasheed A, Samuel M, Zhao W, Bonnycastle LL, Jackson AU, Narisu N, Swift AJ, Southam L, Marten J, Huyghe JR, Stancakova A, Fava C, Ohlsson T, Matchan A, Stirrups KE, Bork-Jensen J, Gjesing AP, Kontto J, Perola M, Shaw-Hawkins S, Havulinna AS, Zhang H, Donnelly LA, Groves CJ, Rayner NW, Neville MJ, Robertson NR, Yliorkas AM, Herzig KH, Kajantie E, Zhang W, Willems SM, Lannfelt L, Malerba G, Soranzo N, Trabetti E, Verweij N, Evangelou E, Moayyeri A, Vergnaud AC, Nelson CP, Poveda A, Varga TV, Caslake M, de Craen AJ, Trompet S, Luan J, Scott RA, Harris SE, Liewald DC, Marioni R, Menni C, Farmaki AE, Hallmans G, Renstrom F, Huffman JE, Hassinen M, Burgess S, Vasani RS, Felix JF; CHARGE-Heart Failure Consortium, Uria-Nickelsen M, Malarstig A, Reily DF, Hoek M, Vogt T, Lin H, Lieb W; EchoGen Consortium, Traylor M, Markus HF; METASTROKE Consortium, Highland HM, Justice AE, Marouli E; GIANT Consortium, Lindström J, Uusitupa M, Komulainen P, Lakka TA, Rauramaa R, Polasek O, Rudan I, Rolandsson O, Franks PW, Dedoussis G, Spector TD; EPIC-InterAct Consortium, Jousilahti P, Männistö S, Deary IJ, Starr JM, Langenberg C, Wareham NJ, Brown MJ, Dominiczak AF, Connell JM, Jukema JW, Sattar N, Ford I, Packard CJ, Esko T, Mägi R, Metspalu A, de Boer RA, van der Meer P, van der Harst P; Lifelines Cohort Study, Gambaro G, Ingelsson E, Lind L, de Bakker PI, Numans ME, Brandslund I, Christensen C, Petersen ER, Korpi-Hyövälti E, Oksa H, Chambers JC, Kooner JS, Blakemore AI, Franks S, Jarvelin MR, Husemoen LL, Linneberg A, Skaaby T, Thuesen B, Karpe F, Tuomilehto J, Doney AS, Morris AD, Palmer CN, Holmen OL, Hveem K, Willer CJ, Tuomi T, Groop L, Käräjämäki A, Palotie A, Ripatti S, Salomaa V, Alam DS, Shafi Majumder AA, Di Angelantonio E, Chowdhury R, McCarthy MI, Poulter N, Stanton AV, Sever P, Amouyel P, Arveiler D, Blankenberg S, Ferrières J, Kee F, Kuulasmaa K, Müller-Nurasyid M, Veronesi G, Virtamo J, Deloukas P; Wellcome Trust Case Control Consortium, Elliott P; Understanding Society Scientific Group, Zeggini E, Kathiresan S, Melander O, Kuusisto J, Laakso M, Padmanabhan S, Porteous D, Hayward C, Scotland G, Collins FS, Mohlke KL, Hansen T, Pedersen O, Boehnke M, Stringham HM; EPIC-CVD Consortium, Frossard P, Newton-Cheh C; CHARGE + Exome Chip Blood Pressure Consortium, Tobin MD, Nordestgaard BG; T2D-GENES Consortium; GoT2DGenes Consortium; ExomeBP Consortium; CHD Exome + Consortium, Caulfield MJ, Mahajan A, Morris AP, Tomaszewski M, Samani NJ, Saleheen D, Asselbergs FW, Lindgren CM, Danesh J, Wain LV, Butterworth AS, Howson JM, Munroe PB. Trans-ancestry meta-analyses identify rare and common variants associated with blood pressure and hypertension. *Nat Genet* 2016; 48(10): 1151–1161
47. Seo HS, Liu DD, Bekele BN, Kim MK, Pisters K, Lippman SM, Wistuba II, Koo JS. Cyclic AMP response element-binding protein

- overexpression: a feature associated with negative prognosis in never smokers with non-small cell lung cancer. *Cancer Res* 2008; 68 (15): 6065–6073
48. Walters CL, Cleck JN, Kuo YC, Blendy JA. Mu-opioid receptor and CREB activation are required for nicotine reward. *Neuron* 2005; 46 (6): 933–943
49. Srinivasan S, Totiger T, Shi C, Castellanos J, Lamichhane P, Dosch AR, Messaggio F, Kashikar N, Honnenahally K, Ban Y, Merchant NB, VanSaun M, Nagathihalli NS. Tobacco carcinogen-induced production of GM-CSF activates CREB to promote pancreatic cancer. *Cancer Res* 2018; 78(21): 6146–6158
50. Hung CC, Kuo CW, Wang WH, Chang TH, Chang PJ, Chang LK, Liu ST. Transcriptional activation of Epstein–Barr virus BRLF1 by USF1 and Rta. *J Gen Virol* 2015; 96(9): 2855–2866
51. Gao E, Wang Y, Alcorn JL, Mendelson CR. The basic helix–loop–helix–zipper transcription factor USF1 regulates expression of the surfactant protein-A gene. *J Biol Chem* 1997; 272(37): 23398–23406
52. Ho PK, Hawkins CJ. Mammalian initiator apoptotic caspases. *FEBS J* 2005; 272(21): 5436–5453
53. MacPherson G, Healey CS, Teare MD, Balasubramanian SP, Reed MW, Pharoah PD, Ponder BA, Meuth M, Bhattacharyya NP, Cox A. Association of a common variant of the CASP8 gene with reduced risk of breast cancer. *J Natl Cancer Inst* 2004; 96(24): 1866–1869
54. Sun T, Gao Y, Tan W, Ma S, Shi Y, Yao J, Guo Y, Yang M, Zhang X, Zhang Q, Zeng C, Lin D. A six-nucleotide insertion-deletion polymorphism in the CASP8 promoter is associated with susceptibility to multiple cancers. *Nat Genet* 2007; 39(5): 605–613
55. Castel SE, Cervera A, Mohammadi P, Aguet F, Reverter F, Wolman A, Guigo R, Iossifov I, Vasileva A, Lappalainen T. Modified penetrance of coding variants by cis-regulatory variation contributes to disease risk. *Nat Genet* 2018; 50(9): 1327–1334
56. Hořejší V, Zhang W, Schraven B. Transmembrane adaptor proteins: organizers of immunoreceptor signalling. *Nat Rev Immunol* 2004; 4 (8): 603–616
57. Brdickova N, Brdicka T, Angelisova P, Horvath O, Spicka J, Hilgert I, Paces J, Simeoni L, Kliche S, Merten C, Schraven B, Horejsi V. LIME: a new membrane Raft-associated adaptor protein involved in CD4 and CD8 coreceptor signaling. *J Exp Med* 2003; 198(10): 1453–1462
58. Lok BH, Powell SN. Molecular pathways: understanding the role of Rad52 in homologous recombination for therapeutic advancement. *Clin Cancer Res* 2012; 18(23): 6400–6406
59. Lisby M, Rothstein R, Mortensen UH. Rad52 forms DNA repair and recombination centers during S phase. *Proc Natl Acad Sci USA* 2001; 98(15): 8276–8282
60. Galanos P, Pappas G, Polyzos A, Kotsinas A, Svolaki I, Giakoumakis NN, Glytsou C, Pateras IS, Swain U, Souliotis VL, Georgakilas AG, Geacintov N, Scorrano L, Lukas C, Lukas J, Livneh Z, Lygerou Z, Chowdhury D, Sorensen CS, Bartek J, Gorgoulis VG. Mutational signatures reveal the role of RAD52 in p53-independent p21-driven genomic instability. *Genome Biol* 2018; 19(1): 37
61. Lieberman R, Xiong D, James M, Han Y, Amos CI, Wang L, You M. Functional characterization of RAD52 as a lung cancer susceptibility gene in the 12p13.33 locus. *Mol Carcinog* 2016; 55 (5): 953–963
62. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. *Cell* 2011; 144(5): 646–674
63. Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune set point. *Nature* 2017; 541(7637): 321–330
64. Lavin Y, Kobayashi S, Leader A, Amir ED, Elefant N, Bigenwald C, Remark R, Sweeney R, Becker CD, Levine JH, Meinhof K, Chow A, Kim-Shulze S, Wolf A, Medaglia C, Li H, Rytlewski JA, Emerson RO, Solovyov A, Greenbaum BD, Sanders C, Vignali M, Beasley MB, Flores R, Gnjatich S, Pe'er D, Rahman A, Amit I, Merad M. Innate immune landscape in early lung adenocarcinoma by paired single-cell analyses. *Cell* 2017; 169(4): 750–765.e17
65. Tiwari S, Tripathy BC, Jajoo A, Das AB, Murata N, Sane PV, Govindjee. Prasanna K. Mohanty (1934–2013): a great photosynthetiker and a wonderful human being who touched the hearts of many. *Photosynth Res* 2014; 122(3): 235–260
66. Hecht SS. Lung carcinogenesis by tobacco smoke. *Int J Cancer* 2012; 131(12): 2724–2732
67. Herbst RS, Baas P, Kim DW, Felip E, Perez-Gracia JL, Han JY, Molina J, Kim JH, Arvis CD, Ahn MJ, Majem M, Fidler MJ, de Castro G Jr, Garrido M, Lubiniecki GM, Shentu Y, Im E, Dolled-Filhart M, Garon EB. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. *Lancet* 2016; 387(10027): 1540–1550
68. Reck M, Rodriguez-Abreu D, Robinson AG, Hui R, Csoszi T, Fulop A, Gottfried M, Peled N, Tafreshi A, Cuffe S, O'Brien M, Rao S, Hotta K, Leiby MA, Lubiniecki GM, Shentu Y, Rangwala R, Brahmer JR. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. *N Engl J Med* 2016; 375(19): 1823–1833